CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03199885
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:43.476792+00:00
Published At: 2025-12-30T00:00:00+00:00
Record Updated At: 2025-12-30
Results Posted At: 2025-12-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Breast Adenocarcinoma", "Metastatic HER2-Positive Breast Carcinoma", "Recurrent Breast Adenocarcinoma", "Recurrent HER2-Positive Breast Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Unresectable Breast Carcinoma", "Unresectable HER2-Positive Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-30"
protocolSection.identificationModule.nctId: "NCT03199885"
protocolSection.identificationModule.officialTitle: "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-12-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.